Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes.
Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. Am J Physiol Regul Integr Comp Physiol. 2006 Feb; 290(2):R435-41.